In the first edition of 2013 of the Dutch magazine Medicines, special attention is paid to Abundnz and its innovative pAMS technology. Medicines is an independent journal writing about drug research in the Netherlands.
In the first edition of 2013 of the Dutch magazine Medicines, special attention is paid to Abundnz and its innovative pAMS technology. Medicines is an independent journal writing about drug research in the Netherlands.
Abundnz and UK based company ImmunoSYS have agreed to work in partnership to further develop and commercialise our pAMS technology. The tool originally developed by Abundnz is expected to offer drug discovery companies an advanced and better analysis option.
Abundnz has partnerships with ImMunoSysLtd, IBIS Technologies, MsMetrix, Van Sonsbeek Software, InnoTherapy and Ducares.